Helicobacter pylori in gastric carcinogenesis

World Journal of Gastrointestinal Oncology

Volumn 7, Issue 12, 2015, Pages 455-465

  Ahn, Hyo Jun ^a   Lee, Dong Soo ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Gastric cancer; Helicobacter pylori

Indexed keywords

EID: 84962223267     PISSN: None     EISSN: 19485204     Source Type: Journal    
DOI: 10.4251/wjgo.v7.i12.455     Document Type: Article

References (123)

1. 1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer2015; 136: E359-E386 [PMID: 25220842 DOI: 10.1002/ijc.29210]
2. 2. de Sablet T, Piazuelo MB, Shaffer CL, Schneider BG, Asim M, Chaturvedi R, Bravo LE, Sicinschi LA, Delgado AG, Mera RM, Israel DA, Romero-Gallo J, Peek RM, Cover TL, Correa P, Wilson KT. Phylogeographic origin of Helicobacter pylori is a determinant of gastric cancer risk. Gut2011; 60: 1189-1195 [PMID: 21357593. DOI: 10.1136/gut.2010.234468]
3. 3. Cancer Reserch UK. Worldwide cancer incidence statistics, 2011. [accessed 2015 May 1]. Available from: URL: http://www.cancerresearchuk.org/cancer-info/cancerstats/world/incidence/#By
4. 4. Schmidt N, Peitz U, Lippert H, Malfertheiner P. Missing gastric cancer in dyspepsia. Aliment Pharmacol Ther2005; 21: 813-820 [PMID: 15801916 DOI: 10.1111/j.1365-2036.2005.02425.x]
5. 5. Figueiredo C, Garcia-Gonzalez MA, Machado JC. Molecular pathogenesis of gastric cancer. Helicobacter2013; 18 Suppl 1: 28-33 [PMID: 24011242 DOI: 10.1111/hel.12083]
6. 6. McLean MH, El-Omar EM. Genetics of gastric cancer. Nat Rev Gastroenterol Hepatol2014; 11: 664-674 [PMID: 25134511 DOI: 10.1038/nrgastro.2014.143]
7. 7. Tan IB, Ng I, Tai WM, Tan P. Understanding the genetic basis of gastric cancer: recent advances. Expert Rev Gastroenterol Hepatol2012; 6: 335-341 [PMID: 22646255 DOI: 10.1586/egh.12.7]
8. 8. de Martel C, Forman D, Plummer M. Gastric cancer: epidemiology and risk factors. Gastroenterol Clin North Am2013; 42: 219-240 [PMID: 23639638 DOI: 10.1016/j.gtc.2013.01.003]
9. 9. Kelley JR, Duggan JM. Gastric cancer epidemiology and risk factors. J Clin Epidemiol2003; 56: 1-9 [PMID: 12589864]
10. 10. Suzuki H, Iwasaki E, Hibi T. Helicobacter pylori and gastric cancer. Gastric Cancer2009; 12: 79-87 [PMID: 19562461 DOI: 10.1007/ s10120-009-0507-x]
11. 11. Polk DB, Peek RM. Helicobacter pylori: gastric cancer and beyond. Nat Rev Cancer2010; 10: 403-414 [PMID: 20495574 DOI: 10.1038/nrc2857]
12. 12. Noto JM, Peek RM. Helicobacter pylori: an overview. Methods Mol Biol2012; 921: 7-10 [PMID: 23015485 DOI: 10.1007/978-1-6 2703-005-2_2]
13. 13. Everhart JE. Recent developments in the epidemiology of Helicobacter pylori. Gastroenterol Clin North Am2000; 29: 559-578 [PMID: 11030073]
14. 14. Wroblewski LE, Peek RM, Wilson KT. Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin Microbiol Rev2010; 23: 713-739 [PMID: 20930071 DOI: 10.1128/ CMR.00011-10]
15. 15. Abrams JA, Wang TC. Adenocarcinoma and other tumors of the stomach. In: Feldman M, Friedman LS, Brandt LJ, eds. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease Pathophysiology/ Diagnosis/Management. 9th ed. Philadelphia, PA: Elsevier Saunders, 2010 [DOI: 10.1016/B978-1-4557-4692-7.00054-5]
16. 16. Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum1994; 61: 1-241 [PMID: 7715068]
17. 17. Honda S, Fujioka T, Tokieda M, Satoh R, Nishizono A, Nasu M. Development of Helicobacter pylori-induced gastric carcinoma in Mongolian gerbils. Cancer Res1998; 58: 4255-4259 [PMID: 9766647]
18. 18. Watanabe T, Tada M, Nagai H, Sasaki S, Nakao M. Helicobacter pylori infection induces gastric cancer in mongolian gerbils. Gastroenterology1998; 115: 642-648 [PMID: 9721161]
19. 19. Bornschein J, Malfertheiner P. Gastric carcinogenesis. Langenbecks Arch Surg2011; 396: 729-742 [PMID: 21611816 DOI: 10.1007/ s00423-011-0810-y]
20. 20. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med2001; 345: 784-789 [PMID: 11556297 DOI: 10.1056/ NEJMoa001999]
21. 21. Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut2001; 49: 347-353 [PMID: 11511555]
22. 22. Peek RM, Crabtree JE. Helicobacter infection and gastric neoplasia. J Pathol2006; 208: 233-248 [PMID: 16362989 DOI: 10.1002/ path.1868]
23. 23. Amieva MR, El-Omar EM. Host-bacterial interactions in Helicobacter pylori infection. Gastroenterology2008; 134: 306-323 [PMID: 18166359 DOI: 10.1053/j.gastro.2007.11.009]
24. 24. Datta De D, Roychoudhury S. To be or not to be: The host genetic factor and beyond in Helicobacter pylori mediated gastro-duodenal diseases. World J Gastroenterol2015; 21: 2883-2895 [PMID: 25780285 DOI: 10.3748/wjg.v21.i10.2883]
25. 25. Ahmed A, Smoot D, Littleton G, Tackey R, Walters CS, Kashanchi F, Allen CR, Ashktorab H. Helicobacter pylori inhibits gastric cell cycle progression. Microbes Infect2000; 2: 1159-1169 [PMID: 11008106]
26. 26. Lee DS, Moss SF. Targeting Helicobacter pylori in gastric carcinogenesis. Expert Opin Ther Targets2007; 11: 757-769 [PMID: 17504014 DOI: 10.1517/14728222.11.6.757]
27. 27. Kamangar F, Dawsey SM, Blaser MJ, Perez-Perez GI, Pietinen P, Newschaffer CJ, Abnet CC, Albanes D, Virtamo J, Taylor PR. Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with Helicobacter pylori seropositivity. J Natl Cancer Inst2006; 98: 1445-1452 [PMID: 17047193 DOI: 10.1093/jnci/djj393]
28. 28. da Costa DM, Dos Santos Pereira E, de Lima Silva-Fernandes IJ, Ferreira MV, Rabenhorst SH. Characterization of Gastric Cardia Tumors: Differences in Helicobacter pylori Strains and Genetic Polymorphisms. Dig Dis Sci2015; 60: 2712-2717 [PMID: 25902748 DOI: 10.1007/s10620-015-3666-0]
29. 29. Kamangar F, Qiao YL, Blaser MJ, Sun XD, Katki H, Fan JH, Perez-Perez GI, Abnet CC, Zhao P, Mark SD, Taylor PR, Dawsey SM. Helicobacter pylori and oesophageal and gastric cancers in a prospective study in China. Br J Cancer2007; 96: 172-176 [PMID: 17179990 DOI: 10.1038/sj.bjc.6603517]
30. 30. Bornschein J, Selgrad M, Warnecke M, Kuester D, Wex T, Malfertheiner P. H. pylori infection is a key risk factor for proximal gastric cancer. Dig Dis Sci2010; 55: 3124-3131 [PMID: 20668939 DOI: 10.1007/s10620-010-1351-x]
31. 31. Crabtree JE, Taylor JD, Wyatt JI, Heatley RV, Shallcross TM, Tompkins DS, Rathbone BJ. Mucosal IgA recognition of Helicobacter pylori 120 kDa protein, peptic ulceration, and gastric pathology. Lancet1991; 338: 332-335 [PMID: 1677696]
32. 32. Kuipers EJ, Pérez-Pérez GI, Meuwissen SG, Blaser MJ. Helicobacter pylori and atrophic gastritis: importance of the cagA status. J Natl Cancer Inst1995; 87: 1777-1780 [PMID: 7473834]
33. 33. Blaser MJ, Perez-Perez GI, Kleanthous H, Cover TL, Peek RM, Chyou PH, Stemmermann GN, Nomura A. Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res1995; 55: 2111-2115 [PMID: 7743510]
34. 34. Parsonnet J, Friedman GD, Orentreich N, Vogelman H. Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. Gut1997; 40: 297-301 [PMID: 9135515]
35. 35. Yamaoka Y, Graham DY. Helicobacter pylori virulence and cancer pathogenesis. Future Oncol2014; 10: 1487-1500 [PMID: 25052757 DOI: 10.2217/fon.14.29]
36. 36. Yamaoka Y. Mechanisms of disease: Helicobacter pylori virulence factors. Nat Rev Gastroenterol Hepatol2010; 7: 629-641 [PMID: 20938460 DOI: 10.1038/nrgastro.2010.154]
37. 37. van Doorn LJ, Figueiredo C, Sanna R, Plaisier A, Schneeberger P, de Boer W, Quint W. Clinical relevance of the cagA, vacA, and iceA status of Helicobacter pylori. Gastroenterology1998; 115: 58-66 [PMID: 9649459]
38. 38. Yamaoka Y, Kikuchi S, el-Zimaity HM, Gutierrez O, Osato MS, Graham DY. Importance of Helicobacter pylori oipA in clinical presentation, gastric inflammation, and mucosal interleukin 8 production. Gastroenterology2002; 123: 414-424 [PMID: 12145793]
39. 39. Yamaoka Y, Kodama T, Gutierrez O, Kim JG, Kashima K, Graham DY. Relationship between Helicobacter pylori iceA, cagA, and vacA status and clinical outcome: studies in four different countries. J Clin Microbiol1999; 37: 2274-2279 [PMID: 10364597]
40. 40. Tegtmeyer N, Wessler S, Backert S. Role of the cag-pathogenicity island encoded type IV secretion system in Helicobacter pylori pathogenesis. FEBS J2011; 278: 1190-1202 [PMID: 21352489 DOI: 10.1111/j.1742-4658.2011.08035.x]
41. 41. Xu X, Liu Z, Fang M, Yu H, Liang X, Li X, Liu X, Chen C, Jia J. Helicobacter pylori CagA induces ornithine decarboxylase upregulation via Src/MEK/ERK/c-Myc pathway: implication for progression of gastric diseases. Exp Biol Med (Maywood) 2012; 237: 435-441 [PMID: 22442341 DOI: 10.1258/ebm.2011.011199]
42. 42. Mueller D, Tegtmeyer N, Brandt S, Yamaoka Y, De Poire E, Sgouras D, Wessler S, Torres J, Smolka A, Backert S. c-Src and c-Abl kinases control hierarchic phosphorylation and function of the CagA effector protein in Western and East Asian Helicobacter pylori strains. J Clin Invest2012; 122: 1553-1566 [PMID: 22378042 DOI: 10.1172/jci61143]
43. 43. Wang F, Meng W, Wang B, Qiao L. Helicobacter pylori-induced gastric inflammation and gastric cancer. Cancer Lett2014; 345: 196-202 [PMID: 23981572 DOI: 10.1016/j.canlet.2013.08.016]
44. 44. Higashi H, Yokoyama K, Fujii Y, Ren S, Yuasa H, Saadat I, Murata-Kamiya N, Azuma T, Hatakeyama M. EPIYA motif is a membrane-targeting signal of Helicobacter pylori virulence factor CagA in mammalian cells. J Biol Chem2005; 280: 23130-23137 [PMID: 15831497 DOI: 10.1074/jbc.M503583200]
45. 45. Naito M, Yamazaki T, Tsutsumi R, Higashi H, Onoe K, Yamazaki S, Azuma T, Hatakeyama M. Influence of EPIYA-repeat polymorphism on the phosphorylation-dependent biological activity of Helicobacter pylori CagA. Gastroenterology2006; 130: 1181-1190 [PMID: 16618412 DOI: 10.1053/j.gastro.2005.12.038]
46. 46. Hatakeyama M. Anthropological and clinical implications for the structural diversity of the Helicobacter pylori CagA oncoprotein. Cancer Sci2011; 102: 36-43 [PMID: 20942897 DOI: 10.1111/ j.1349-7006.2010.01743.x]
47. 47. Basso D, Zambon CF, Letley DP, Stranges A, Marchet A, Rhead JL, Schiavon S, Guariso G, Ceroti M, Nitti D, Rugge M, Plebani M, Atherton JC. Clinical relevance of Helicobacter pylori cagA and vacA gene polymorphisms. Gastroenterology2008; 135: 91-99 [PMID: 18474244 DOI: 10.1053/j.gastro.2008.03.041]
48. 48. Jones KR, Jang S, Chang JY, Kim J, Chung IS, Olsen CH, Merrell DS, Cha JH. Polymorphisms in the intermediate region of VacA impact Helicobacter pylori-induced disease development. J Clin Microbiol2011; 49: 101-110 [PMID: 21084502 DOI: 10.1128/ jcm.01782-10]
49. 49. Vilaichone RK, Mahachai V, Tumwasorn S, Wu JY, Graham DY, Yamaoka Y. Molecular epidemiology and outcome of Helicobacter pylori infection in Thailand: a cultural cross roads. Helicobacter2004; 9: 453-459 [PMID: 15361085 DOI: 10.1111/ j.1083-4389.2004.00260.x]
50. 50. Hirai I, Sasaki T, Kimoto A, Yamamoto Y, Azuma T, Mahachai V, Hansomburana P, Lertkupinit C, Luangjaru S, Noophan P, Chanatrirattanapan R, Piyanirandr V, Sappajit T, Suthivarakom K, Sangsuk L, Wangroongsarb P. Infection of less virulent Helicobacter pylori strains in asymptomatic healthy individuals in Thailand as a potential contributing factor to the Asian enigma. Microbes Infect2010; 12: 227-230 [PMID: 20036753 DOI: 10.1016/ j.micinf.2009.12.007]
51. 51. Argent RH, Thomas RJ, Aviles-Jimenez F, Letley DP, Limb MC, El-Omar EM, Atherton JC. Toxigenic Helicobacter pylori infection precedes gastric hypochlorhydria in cancer relatives, and H. pylori virulence evolves in these families. Clin Cancer Res2008; 14: 2227-2235 [PMID: 18381965 DOI: 10.1158/1078-0432. ccr-07-2022]
52. 52. Zhang XS, Tegtmeyer N, Traube L, Jindal S, Perez-Perez G, Sticht H, Backert S, Blaser MJ. A specific A/T polymorphism in Western tyrosine phosphorylation B-motifs regulates Helicobacter pylori CagA epithelial cell interactions. PLoS Pathog2015; 11: e1004621 [PMID: 25646814 DOI: 10.1371/journal.ppat.1004621]
53. 53. Yahiro K, Wada A, Nakayama M, Kimura T, Ogushi K, Niidome T, Aoyagi H, Yoshino K, Yonezawa K, Moss J, Hirayama T. Protein-tyrosine phosphatase alpha, RPTP alpha, is a Helicobacter pylori VacA receptor. J Biol Chem2003; 278: 19183-19189 [PMID: 12626515 DOI: 10.1074/jbc.M300117200]
54. 54. Gebert B, Fischer W, Weiss E, Hoffmann R, Haas R. Helicobacter pylori vacuolating cytotoxin inhibits T lymphocyte activation. Science2003; 301: 1099-1102 [PMID: 12934009 DOI: 10.1126/ science.1086871]
55. 55. Atherton JC, Cao P, Peek RM, Tummuru MK, Blaser MJ, Cover TL. Mosaicism in vacuolating cytotoxin alleles of Helicobacter pylori. Association of specific vacA types with cytotoxin production and peptic ulceration. J Biol Chem1995; 270: 17771-17777 [PMID: 7629077]
56. 56. Rhead JL, Letley DP, Mohammadi M, Hussein N, Mohagheghi MA, Eshagh Hosseini M, Atherton JC. A new Helicobacter pylori vacuolating cytotoxin determinant, the intermediate region, is associated with gastric cancer. Gastroenterology2007; 133: 926-936 [PMID: 17854597 DOI: 10.1053/j.gastro.2007.06.056]
57. 57. Sugimoto M, Zali MR, Yamaoka Y. The association of vacA genotypes and Helicobacter pylori-related gastroduodenal diseases in the Middle East. Eur J Clin Microbiol Infect Dis2009; 28: 1227-1236 [PMID: 19551413 DOI: 10.1007/s10096-009-0772-y]
58. 58. Sugimoto M, Yamaoka Y. The association of vacA genotype and Helicobacter pylori-related disease in Latin American and African populations. Clin Microbiol Infect2009; 15: 835-842 [PMID: 19392900 DOI: 10.1111/j.1469-0691.2009.02769.x]
59. 59. Ferreira RM, Machado JC, Letley D, Atherton JC, Pardo ML, Gonzalez CA, Carneiro F, Figueiredo C. A novel method for genotyping the Helicobacter pylori vacA intermediate region directly in gastric biopsy specimens. J Clin Microbiol2012; 50: 3983-3989 [PMID: 23035185 DOI: 10.1128/jcm.02087-12]
60. 60. Douraghi M, Talebkhan Y, Zeraati H, Ebrahimzadeh F, Nahvijoo A, Morakabati A, Ghafarpour M, Esmaili M, Bababeik M, Oghalaie A, Rakhshani N, Hosseini ME, Mohagheghi MA, Mohammadi M. Multiple gene status in Helicobacter pylori strains and risk of gastric cancer development. Digestion2009; 80: 200-207 [PMID: 19752557 DOI: 10.1159/000229774]
61. 61. Memon AA, Hussein NR, Miendje Deyi VY, Burette A, Atherton JC. Vacuolating cytotoxin genotypes are strong markers of gastric cancer and duodenal ulcer-associated Helicobacter pylori strains: a matched case-control study. J Clin Microbiol2014; 52: 2984-2989 [PMID: 24920772 DOI: 10.1128/jcm.00551-14]
62. 62. Ferreira RM, Figueiredo C, Bonet C, Pardo ML, Liso JM, Alonso P, Sala N, Capella G, Sanz-Anquela JM, González CA. Helicobacter pylori vacA intermediate region genotyping and progression of gastric preneoplastic lesions. Am J Gastroenterol2012; 107: 145-146 [PMID: 22218041 DOI: 10.1038/ajg.2011.389]
63. 63. El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, Herrera J, Lissowska J, Yuan CC, Rothman N, Lanyon G, Martin M, Fraumeni JF, Rabkin CS. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature2000; 404: 398-402 [PMID: 10746728 DOI: 10.1038/35006081]
64. 64. El-Omar EM, Rabkin CS, Gammon MD, Vaughan TL, Risch HA, Schoenberg JB, Stanford JL, Mayne ST, Goedert J, Blot WJ, Fraumeni JF, Chow WH. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology2003; 124: 1193-1201 [PMID: 12730860]
65. 65. Machado JC, Figueiredo C, Canedo P, Pharoah P, Carvalho R, Nabais S, Castro Alves C, Campos ML, Van Doorn LJ, Caldas C, Seruca R, Carneiro F, Sobrinho-Simões M. A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology2003; 125: 364-371 [PMID: 12891537]
66. 66. Figueiredo C, Machado JC, Pharoah P, Seruca R, Sousa S, Carvalho R, Capelinha AF, Quint W, Caldas C, van Doorn LJ, Carneiro F, Sobrinho-Simões M. Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst2002; 94: 1680-1687 [PMID: 12441323]
67. 67. Furuta T, El-Omar EM, Xiao F, Shirai N, Takashima M, Sugimura H. Interleukin 1beta polymorphisms increase risk of hypochlorhydria and atrophic gastritis and reduce risk of duodenal ulcer recurrence in Japan. Gastroenterology2002; 123: 92-105 [PMID: 12105837]
68. 68. Zeng ZR, Hu PJ, Hu S, Pang RP, Chen MH, Ng M, Sung JJ. Association of interleukin 1B gene polymorphism and gastric cancers in high and low prevalence regions in China. Gut2003; 52: 1684-1689 [PMID: 14633943]
69. 69. Rad R, Prinz C, Neu B, Neuhofer M, Zeitner M, Voland P, Becker I, Schepp W, Gerhard M. Synergistic effect of Helicobacter pylori virulence factors and interleukin-1 polymorphisms for the development of severe histological changes in the gastric mucosa. J Infect Dis2003; 188: 272-281 [PMID: 12854083 DOI: 10.1086/376458]
70. 70. Palli D, Saieva C, Luzzi I, Masala G, Topa S, Sera F, Gemma S, Zanna I, D’Errico M, Zini E, Guidotti S, Valeri A, Fabbrucci P, Moretti R, Testai E, del Giudice G, Ottini L, Matullo G, Dogliotti E, Gomez-Miguel MJ. Interleukin-1 gene polymorphisms and gastric cancer risk in a high-risk Italian population. Am J Gastroenterol2005; 100: 1941-1948 [PMID: 16128937 DOI: 10.1111/ j.1572-0241.2005.50084.x]
71. 71. Garza-González E, Bosques-Padilla FJ, El-Omar E, Hold G, Tijerina-Menchaca R, Maldonado-Garza HJ, Pérez-Pérez GI. Role of the polymorphic IL-1B, IL-1RN and TNF-A genes in distal gastric cancer in Mexico. Int J Cancer2005; 114: 237-241 [PMID: 15540224 DOI: 10.1002/ijc.20718]
72. 72. Tu S, Bhagat G, Cui G, Takaishi S, Kurt-Jones EA, Rickman B, Betz KS, Penz-Oesterreicher M, Bjorkdahl O, Fox JG, Wang TC. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell2008; 14: 408-419 [PMID: 18977329 DOI: 10.1016/ j.ccr.2008.10.011]
73. 73. Camargo MC, Mera R, Correa P, Peek RM, Fontham ET, Goodman KJ, Piazuelo MB, Sicinschi L, Zabaleta J, Schneider BG. Interleukin-1beta and interleukin-1 receptor antagonist gene polymorphisms and gastric cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev2006; 15: 1674-1687 [PMID: 16985030 DOI: 10.1158/1055-9965. epi-06-0189]
74. 74. Kamangar F, Cheng C, Abnet CC, Rabkin CS. Interleukin-1B polymorphisms and gastric cancer risk–a meta-analysis. Cancer Epidemiol Biomarkers Prev2006; 15: 1920-1928 [PMID: 17035400 DOI: 10.1158/1055-9965.epi-06-0267]
75. 75. Persson C, Canedo P, Machado JC, El-Omar EM, Forman D. Polymorphisms in inflammatory response genes and their association with gastric cancer: A HuGE systematic review and meta-analyses. Am J Epidemiol2011; 173: 259-270 [PMID: 21178102 DOI: 10.1093/aje/kwq370]
76. 76. Xue H, Lin B, Ni P, Xu H, Huang G. Interleukin-1B and interleukin-1 RN polymorphisms and gastric carcinoma risk: a meta-analysis. J Gastroenterol Hepatol2010; 25: 1604-1617 [PMID: 20880168 DOI: 10.1111/j.1440-1746.2010.06428.x]
77. 77. Hold GL, Rabkin CS, Chow WH, Smith MG, Gammon MD, Risch HA, Vaughan TL, McColl KE, Lissowska J, Zatonski W, Schoenberg JB, Blot WJ, Mowat NA, Fraumeni JF, El-Omar EM. A functional polymorphism of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology2007; 132: 905-912 [PMID: 17324405 DOI: 10.1053/j.gastro.2006.12.026]
78. 78. Sakamoto H, Yoshimura K, Saeki N, Katai H, Shimoda T, Matsuno Y, Saito D, Sugimura H, Tanioka F, Kato S, Matsukura N, Matsuda N, Nakamura T, Hyodo I, Nishina T, Yasui W, Hirose H, Hayashi M, Toshiro E, Ohnami S, Sekine A, Sato Y, Totsuka H, Ando M, Takemura R, Takahashi Y, Ohdaira M, Aoki K, Honmyo I, Chiku S, Aoyagi K, Sasaki H, Ohnami S, Yanagihara K, Yoon KA, Kook MC, Lee YS, Park SR, Kim CG, Choi IJ, Yoshida T, Nakamura Y, Hirohashi S. Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat Genet2008; 40: 730-740 [PMID: 18488030 DOI: 10.1038/ng.152]
79. 79. Shi D, Wang S, Gu D, Wu D, Wang M, Chu H, Tong N, Ma L, Zhong D, Zhang Z. The PSCA polymorphisms derived from genome-wide association study are associated with risk of gastric cancer: a meta-analysis. J Cancer Res Clin Oncol2012; 138: 1339-1345 [PMID: 22481254 DOI: 10.1007/s00432-012-1210-6]
80. 80. Qiao L, Feng Y. Genetic variations of prostate stem cell antigen (PSCA) contribute to the risk of gastric cancer for Eastern Asians: a meta-analysis based on 16792 individuals. Gene2012; 493: 83-91 [PMID: 22155405 DOI: 10.1016/j.gene.2011.11.017]
81. 81. Sala N, Muñoz X, Travier N, Agudo A, Duell EJ, Moreno V, Overvad K, Tjonneland A, Boutron-Ruault MC, Clavel-Chapelon F, Canzian F, Kaaks R, Boeing H, Meidtner K, Trichopoulos A, Tsiotas K, Zylis D, Vineis P, Panico S, Palli D, Krogh V, Tumino R, Lund E, Bueno-de-Mesquita HB, Numans ME, Peeters PH, Quirós JR, Sánchez MJ, Navarro C, Ardanaz E, Dorronsoro M, Hallmans G, Stenling R, Manjer J, Allen NE, Travis RC, Khaw KT, Jenab M, Offerhaus GJ, Riboli E, González CA. Prostate stem-cell antigen gene is associated with diffuse and intestinal gastric cancer in Caucasians: results from the EPIC-EURGAST study. Int J Cancer2012; 130: 2417-2427 [PMID: 21681742 DOI: 10.1002/ijc.26243]
82. 82. Lochhead P, Frank B, Hold GL, Rabkin CS, Ng MT, Vaughan TL, Risch HA, Gammon MD, Lissowska J, Weck MN, Raum E, Müller H, Illig T, Klopp N, Dawson A, McColl KE, Brenner H, Chow WH, El-Omar EM. Genetic variation in the prostate stem cell antigen gene and upper gastrointestinal cancer in white individuals. Gastroenterology2011; 140: 435-441 [PMID: 21070776 DOI: 10.1053/j.gastro.2010.11.001]
83. 83. Shikata K, Kiyohara Y, Kubo M, Yonemoto K, Ninomiya T, Shirota T, Tanizaki Y, Doi Y, Tanaka K, Oishi Y, Matsumoto T, Iida M. A prospective study of dietary salt intake and gastric cancer incidence in a defined Japanese population: the Hisayama study. Int J Cancer2006; 119: 196-201 [PMID: 16450397 DOI: 10.1002/ijc.21822]
84. 84. Gaddy JA, Radin JN, Loh JT, Zhang F, Washington MK, Peek RM, Algood HM, Cover TL. High dietary salt intake exacerbates Helicobacter pylori-induced gastric carcinogenesis. Infect Immun2013; 81: 2258-2267 [PMID: 23569116 DOI: 10.1128/iai.01271-12]
85. 85. Liu C, Russell RM. Nutrition and gastric cancer risk: an update. Nutr Rev2008; 66: 237-249 [PMID: 18454810 DOI: 10.1111/ j.1753-4887.2008.00029.x]
86. 86. Toyoda T, Tsukamoto T, Hirano N, Mizoshita T, Kato S, Takasu S, Ban H, Tatematsu M. Synergistic upregulation of inducible nitric oxide synthase and cyclooxygenase-2 in gastric mucosa of Mongolian gerbils by a high-salt diet and Helicobacter pylori infection. Histol Histopathol2008; 23: 593-599 [PMID: 18283644]
87. 87. Loh JT, Torres VJ, Cover TL. Regulation of Helicobacter pylori cagA expression in response to salt. Cancer Res2007; 67: 4709-4715 [PMID: 17510398 DOI: 10.1158/0008-5472.can-06-4746]
88. 88. Gancz H, Jones KR, Merrell DS. Sodium chloride affects Helicobacter pylori growth and gene expression. J Bacteriol2008; 190: 4100-4105 [PMID: 18375562 DOI: 10.1128/jb.01728-07]
89. 89. Ladeiras-Lopes R, Pereira AK, Nogueira A, Pinheiro-Torres T, Pinto I, Santos-Pereira R, Lunet N. Smoking and gastric cancer: systematic review and meta-analysis of cohort studies. Cancer Causes Control2008; 19: 689-701 [PMID: 18293090 DOI: 10.1007/s10552-008-9132-y]
90. 90. Falush D, Wirth T, Linz B, Pritchard JK, Stephens M, Kidd M, Blaser MJ, Graham DY, Vacher S, Perez-Perez GI, Yamaoka Y, Mégraud F, Otto K, Reichard U, Katzowitsch E, Wang X, Achtman M, Suerbaum S. Traces of human migrations in Helicobacter pylori populations. Science2003; 299: 1582-1585 [PMID: 12624269 DOI: 10.1126/science.1080857]
91. 91. Kodaman N, Pazos A, Schneider BG, Piazuelo MB, Mera R, Sobota RS, Sicinschi LA, Shaffer CL, Romero-Gallo J, de Sablet T, Harder RH, Bravo LE, Peek RM, Wilson KT, Cover TL, Williams SM, Correa P. Human and Helicobacter pylori coevolution shapes the risk of gastric disease. Proc Natl Acad Sci USA2014; 111: 1455-1460 [PMID: 24474772 DOI: 10.1073/pnas.1318093111]
92. 92. Park JY, von Karsa L, Herrero R. Prevention strategies for gastric cancer: a global perspective. Clin Endosc2014; 47: 478-489 [PMID: 25505712 DOI: 10.5946/ce.2014.47.6.478]
93. 93. Lee JK, Park BJ, Yoo KY, Ahn YO. Dietary factors and stomach cancer: a case-control study in Korea. Int J Epidemiol1995; 24: 33-41 [PMID: 7797354]
94. 94. Hirayama T. Nutrition and cancer–a large scale cohort study. Prog Clin Biol Res1986; 206: 299-311 [PMID: 3952095]
95. 95. Wang Q, Chen Y, Wang X, Gong G, Li G, Li C. Consumption of fruit, but not vegetables, may reduce risk of gastric cancer: results from a meta-analysis of cohort studies. Eur J Cancer2014; 50: 1498-1509 [PMID: 24613128 DOI: 10.1016/j.ejca.2014.02.009]
96. 96. Guercio V, Galeone C, Turati F, La Vecchia C. Gastric cancer and allium vegetable intake: a critical review of the experimental and epidemiologic evidence. Nutr Cancer2014; 66: 757-773 [PMID: 24820444 DOI: 10.1080/01635581.2014.904911]
97. 97. Loh YH, Jakszyn P, Luben RN, Mulligan AA, Mitrou PN, Khaw KT. N-Nitroso compounds and cancer incidence: the European Prospective Investigation into Cancer and Nutrition (EPIC)-Norfolk Study. Am J Clin Nutr2011; 93: 1053-1061 [PMID: 21430112 DOI: 10.3945/ajcn.111.012377]
98. 98. Jakszyn P, Bingham S, Pera G, Agudo A, Luben R, Welch A, Boeing H, Del Giudice G, Palli D, Saieva C, Krogh V, Sacerdote C, Tumino R, Panico S, Berglund G, Simán H, Hallmans G, Sanchez MJ, Larrañaga N, Barricarte A, Chirlaque MD, Quirós JR, Key TJ, Allen N, Lund E, Carneiro F, Linseisen J, Nagel G, Overvad K, Tjonneland A, Olsen A, Bueno-de-Mesquita HB, Ocké MO, Peeters PH, Numans ME, Clavel-Chapelon F, Trichopoulou A, Fenger C, Stenling R, Ferrari P, Jenab M, Norat T, Riboli E, Gonzalez CA. Endogenous versus exogenous exposure to N-nitroso compounds and gastric cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST) study. Carcinogenesis2006; 27: 1497-1501 [PMID: 16571648 DOI: 10.1093/carcin/bgl019]
99. 99. Buckland G, Travier N, Huerta JM, Bueno-de-Mesquita HB, Siersema PD, Skeie G, Weiderpass E, Engeset D, Ericson U, Ohlsson B, Agudo A, Romieu I, Ferrari P, Freisling H, Colorado-Yohar S, Li K, Kaaks R, Pala V, Cross AJ, Riboli E, Trichopoulou A, Lagiou P, Bamia C, Boutron-Ruault MC, Fagherazzi G, Dartois L, May AM, Peeters PH, Panico S, Johansson M, Wallner B, Palli D, Key TJ, Khaw KT, Ardanaz E, Overvad K, Tjønneland A, Dorronsoro M, Sánchez MJ, Quirós JR, Naccarati A, Tumino R, Boeing H, Gonzalez CA. Healthy lifestyle index and risk of gastric adenocarcinoma in the EPIC cohort study. Int J Cancer2015; 137: 598-606 [PMID: 25557932 DOI: 10.1002/ijc.29411]
100. 100. Ford AC, Forman D, Hunt RH, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ2014; 348: g3174 [PMID: 24846275 DOI: 10.1136/bmj.g3174]
101. 101. Ma JL, Zhang L, Brown LM, Li JY, Shen L, Pan KF, Liu WD, Hu Y, Han ZX, Crystal-Mansour S, Pee D, Blot WJ, Fraumeni JF, You WC, Gail MH. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J Natl Cancer Inst2012; 104: 488-492 [PMID: 22271764 DOI: 10.1093/jnci/djs003]
102. 102. Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham D Y, Rokkas T, El-Omar EM, Kuipers EJ. Management of Helicobacter pylori infection–the Maastricht IV/ Florence Consensus Report. Gut2012; 61: 646-664 [PMID: 22491499 DOI: 10.1136/gutjnl-2012-302084]
103. 103. Liu WZ, Xie Y, Cheng H, Lu NH, Hu FL, Zhang WD, Zhou LY, Chen Y, Zeng ZR, Wang CW, Xiao SD, Pan GZ, Hu PJ. Fourth Chinese National Consensus Report on the management of Helicobacter pylori infection. J Dig Dis2013; 14: 211-221 [PMID: 23302262 DOI: 10.1111/1751-2980.12034]
104. 104. Kim SG, Jung HK, Lee HL, Jang JY, Lee H, Kim CG, Shin WG, Shin ES, Lee YC. [Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition]. Korean J Gastroenterol2013; 62: 3-26 [PMID: 23954956 DOI: 10.4166/kjg.2013.62.1.3]
105. 105. Fock KM, Katelaris P, Sugano K, Ang TL, Hunt R, Talley NJ, Lam SK, Xiao SD, Tan HJ, Wu CY, Jung HC, Hoang BH, Kachintorn U, Goh KL, Chiba T, Rani AA. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol2009; 24: 1587-1600 [PMID: 19788600 DOI: 10.1111/ j.1440-1746.2009.05982.x]
106. 106. Asaka M, Kato M, Takahashi S, Fukuda Y, Sugiyama T, Ota H, Uemura N, Murakami K, Satoh K, Sugano K. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter2010; 15: 1-20 [PMID: 20302585 DOI: 10.1111/j.1523-5378.2009.00738.x]
107. 107. Lee JY, Kim N. [Future trends of Helicobacter pylori eradication therapy in Korea]. Korean J Gastroenterol2014; 63: 158-170 [PMID: 24651589 DOI: 10.4166/kjg.2014.63.3.158]
108. 108. Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, Haruma K, Asaka M, Uemura N, Malfertheiner P. Kyoto global consensus report on Helicobacter pylori gastritis. Gut2015; 64: 1353-1367 [PMID: 26187502 DOI: 10.1136/gutjnl-2015-309252]
109. 109. Oh HS, Lee DH, Seo JY, Cho YR, Kim N, Jeoung SH, Kim JW, Hwang JH, Park YS, Lee SH, Shin CM, Cho HJ, Jung HC, Song IS. Ten-day sequential therapy is more effective than proton pump inhibitor-based therapy in Korea: a prospective, randomized study. J Gastroenterol Hepatol2012; 27: 504-509 [PMID: 21916989 DOI: 10.1111/j.1440-1746.2011.06922.x]
110. 110. Nishizawa T, Suzuki H, Suzuki M, Takahashi M, Hibi T. Proton pump inhibitor-amoxicillin-clarithromycin versus proton pump inhibitor-amoxicillin-metronidazole as frst-line Helicobacter pylori eradication therapy. J Clin Biochem Nutr2012; 51: 114-116 [PMID: 22962528 DOI: 10.3164/jcbn.D-11-00029R1]
111. 111. Basu PP, Rayapudi K, Pacana T, Shah NJ, Krishnaswamy N, Flynn M. A randomized study comparing levofoxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. Am J Gastroenterol2011; 106: 1970-1975 [PMID: 21989146 DOI: 10.1038/ajg.2011.306]
112. 112. Boyanova L, Mitov I. Geographic map and evolution of primary Helicobacter pylori resistance to antibacterial agents. Expert Rev Anti Infect Ther2010; 8: 59-70 [PMID: 20014902 DOI: 10.1586/ eri.09.113]
113. 113. De Francesco V, Giorgio F, Hassan C, Manes G, Vannella L, Panella C, Ierardi E, Zullo A. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis2010; 19: 409-414 [PMID: 21188333]
114. 114. Kobayashi I, Murakami K, Kato M, Kato S, Azuma T, Takahashi S, Uemura N, Katsuyama T, Fukuda Y, Haruma K, Nasu M, Fujioka T. Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005. J Clin Microbiol2007; 45: 4006-4010 [PMID: 17942652 DOI: 10.1128/ jcm.00740-07]
115. 115. Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, Andersen LP, Goossens H, Glupczynski Y. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut2013; 62: 34-42 [PMID: 22580412 DOI: 10.1136/ gutjnl-2012-302254]
116. 116. Miyachi H, Miki I, Aoyama N, Shirasaka D, Matsumoto Y, Toyoda M, Mitani T, Morita Y, Tamura T, Kinoshita S, Okano Y, Kumagai S, Kasuga M. Primary levofoxacin resistance and gyrA/B mutations among Helicobacter pylori in Japan. Helicobacter2006; 11: 243-249 [PMID: 16882327 DOI: 10.1111/j.1523-5378.2006.00415.x]
117. 117. Kim KB, Kim YS. Recent Trends of Helicobacter pylori Eradication Therapy: Focusing on First Line Treatment. Korean J Helicobacter Up Gastrointest Res2014; 14: 237-241 [DOI: 10.7704/ kjhugr.2014.14.4.237]
118. 118. Yamac D, Ayyildiz T, Coşkun U, Akyürek N, Dursun A, Seckin S, Koybasioglu F. Cyclooxygenase-2 expression and its association with angiogenesis, Helicobacter pylori, and clinicopathologic characteristics of gastric carcinoma. Pathol Res Pract2008; 204: 527-536 [PMID: 18462890 DOI: 10.1016/j.prp.2008.01.002]
119. 119. Shao Y, Sun K, Xu W, Li XL, Shen H, Sun WH. Helicobacter pylori infection, gastrin and cyclooxygenase-2 in gastric carcinogenesis. World J Gastroenterol2014; 20: 12860-12873 [PMID: 25278683 DOI: 10.3748/wjg.v20.i36.12860]
120. 120. He XP, Shao Y, Li XL, Xu W, Chen GS, Sun HH, Xu HC, Xu X, Tang D, Zheng XF, Xue YP, Huang GC, Sun WH. Downregulation of miR-101 in gastric cancer correlates with cyclooxygenase-2 overexpression and tumor growth. FEBS J2012; 279: 4201-4212 [PMID: 23013439 DOI: 10.1111/febs.12013]
121. 121. Tseng YC, Tsai YH, Tseng MJ, Hsu KW, Yang MC, Huang KH, Li AF, Chi CW, Hsieh RH, Ku HH, Yeh TS. Notch2-induced COX-2 expression enhancing gastric cancer progression. Mol Carcinog2012; 51: 939-951 [PMID: 21976141 DOI: 10.1002/mc.20865]
122. 122. Tan VP, Wong BC. Gastric cancer chemoprevention: the current evidence. Gastroenterol Clin North Am2013; 42: 299-316 [PMID: 23639642 DOI: 10.1016/j.gtc.2013.02.001]
123. 123. Zhang MM, Qian W, Qin YY, He J, Zhou YH. Probiotics in Helicobacter pylori eradication therapy: a systematic review and meta-analysis. World J Gastroenterol2015; 21: 4345-4357 [PMID: 25892886 DOI: 10.3748/wjg.v21.i14.4345]